PFE · News · 20260930N

Competition and Market Share

PFIZER INC · 2026-09-30 · Importance 31 · Surprise 42

Invivyd reported that its COVID-19 monoclonal antibody VYD2311 demonstrated superior safety and tolerability versus Pfizer and BioNTech’s Comirnaty in a Phase III study. The result introduces a potential competing COVID-19 protection option as skepticism toward existing vaccines grows. Invivyd plans to submit a Biologics License Application after completing additional trial work, although a separate study’s delayed topline readout remains a development risk.

Key facts

• Pfizer's stock has seen a 20.6% return over the past year. source
• The company's P/E ratio is 37.7x, which is above the broader pharmaceuticals sector average but below a peer group average. source
• Pfizer's stock is currently trading at US$28.72. source